Acrivon Therapeutics (ACRV) Competitors $1.15 -0.10 (-8.00%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.17 +0.02 (+1.74%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. KRRO, ACRS, FATE, EPRX, IKT, GLSI, PLX, TARA, SLN, and FTLFShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Korro Bio (KRRO), Aclaris Therapeutics (ACRS), Fate Therapeutics (FATE), Eupraxia Pharmaceuticals (EPRX), Inhibikase Therapeutics (IKT), Greenwich LifeSciences (GLSI), Protalix BioTherapeutics (PLX), Protara Therapeutics (TARA), Silence Therapeutics (SLN), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Korro Bio Aclaris Therapeutics Fate Therapeutics Eupraxia Pharmaceuticals Inhibikase Therapeutics Greenwich LifeSciences Protalix BioTherapeutics Protara Therapeutics Silence Therapeutics FitLife Brands Acrivon Therapeutics (NASDAQ:ACRV) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Does the media refer more to ACRV or KRRO? In the previous week, Acrivon Therapeutics had 11 more articles in the media than Korro Bio. MarketBeat recorded 19 mentions for Acrivon Therapeutics and 8 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.45 beat Acrivon Therapeutics' score of 0.13 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Korro Bio 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, ACRV or KRRO? Acrivon Therapeutics has higher earnings, but lower revenue than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$60.39M-$2.22-0.52Korro Bio$4.82M28.83-$81.17M-$9.44-1.57 Does the MarketBeat Community believe in ACRV or KRRO? Acrivon Therapeutics received 8 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 95.24% of users gave Acrivon Therapeutics an outperform vote. CompanyUnderperformOutperformAcrivon TherapeuticsOutperform Votes4095.24% Underperform Votes24.76%Korro BioOutperform Votes32100.00% Underperform VotesNo Votes Is ACRV or KRRO more profitable? Acrivon Therapeutics' return on equity of -47.95% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -47.95% -43.73% Korro Bio N/A -50.25%-38.48% Do analysts rate ACRV or KRRO? Acrivon Therapeutics presently has a consensus target price of $17.71, suggesting a potential upside of 1,440.37%. Korro Bio has a consensus target price of $102.43, suggesting a potential upside of 592.08%. Given Acrivon Therapeutics' higher possible upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Korro Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more volatility and risk, ACRV or KRRO? Acrivon Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.66, indicating that its stock price is 166% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ACRV or KRRO? 71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 8.5% of Acrivon Therapeutics shares are held by insiders. Comparatively, 4.6% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryAcrivon Therapeutics beats Korro Bio on 10 of the 17 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.06M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-0.438.9226.8019.71Price / SalesN/A252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book0.216.466.804.50Net Income-$60.39M$143.98M$3.23B$248.18M7 Day Performance4.55%2.03%1.53%0.23%1 Month Performance-43.35%4.11%10.05%12.39%1 Year Performance-86.58%-2.87%16.75%7.07% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics3.1818 of 5 stars$1.15-8.0%$17.71+1,440.4%-86.0%$36.06MN/A-0.4358Analyst RevisionHigh Trading VolumeKRROKorro Bio1.9939 of 5 stars$15.71+4.0%$102.43+552.0%-70.9%$147.53M$4.82M-1.6670Analyst RevisionACRSAclaris Therapeutics2.8689 of 5 stars$1.30-0.8%$10.00+669.2%+9.3%$140.77M$17.78M-2.50100Positive NewsFATEFate Therapeutics4.3512 of 5 stars$1.22+14.0%$4.14+239.6%-68.4%$139.82M$13.34M-0.74550Gap UpEPRXEupraxia Pharmaceuticals2.2038 of 5 stars$3.90+1.6%$10.50+169.2%+32.3%$139.81MN/A-5.4229IKTInhibikase Therapeutics1.5045 of 5 stars$1.87-7.0%$6.50+247.6%+4.2%$139.02M$260,000.00-0.706Gap DownGLSIGreenwich LifeSciences1.1962 of 5 stars$10.18+4.5%$39.00+283.1%-28.1%$135.13MN/A-12.723Positive NewsEarnings ReportPLXProtalix BioTherapeutics2.1884 of 5 stars$1.68+0.6%$15.00+792.9%+40.2%$133.74M$59.76M-12.92200TARAProtara Therapeutics2.1908 of 5 stars$3.42+7.2%$20.40+496.5%+10.9%$131.95MN/A-1.2130Positive NewsSLNSilence Therapeutics3.5258 of 5 stars$4.96+13.5%$33.83+582.1%-78.5%$130.79M$27.70M-3.16100FTLFFitLife Brands4.4294 of 5 stars$13.79+1.1%$20.50+48.7%+0.0%$129.41M$64.47M16.3220Earnings Report Related Companies and Tools Related Companies Korro Bio Competitors Aclaris Therapeutics Competitors Fate Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Inhibikase Therapeutics Competitors Greenwich LifeSciences Competitors Protalix BioTherapeutics Competitors Protara Therapeutics Competitors Silence Therapeutics Competitors FitLife Brands Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
